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Abstract.  Transforming  growth factor-/~ (TGF-B)  is a 
multifunctional regulatory peptide that can inhibit or 
promote the proliferation of cultured vascular smooth 
muscle cells (SMCs), depending on cell density (Ma- 
jack, R. A.  1987. J.  Cell Biol.  105:465-471).  In this 
study, we have examined the mechanisms underlying 
the growth-promoting effects of TGF-/~ in confluent 
SMC cultures.  In mitogenesis assays using confluent 
cells, TGF-~ was found to potentiate the stimulatory 
effects of serum,  PDGF, and basic fibroblast growth 
factor (bFGF), and was shown to act individually as a 
mitogen for SMC. In gene and protein expression ex- 
periments,  TGF-/3 was found to regulate the expression 
of PDGF-A and thrombospondin,  two potential media- 
tors of SMC proliferative events. The induction of 
thrombospondin protein and mRNA was density- 
dependent, delayed relative to its induction by PDGF 
and, based on cycloheximide experiments,  appeared to 
depend on the de novo synthesis of an intermediary 
protein (probably PDGF-A). The relationship between 
PDGF-A expression and TGF-/3-mediated mitogenesis 
was investigated,  and it was determined that a PDGF- 
like activity (probably PDGF-A) was the biological 
mediator of the growth-stimulatory effects of TGF-/3 
on confluent SMC. The effects of purified homodimers 
of PDGF-A on SMC replication were investigated,  and 
it was determined that PDGF-AA was mitogenic for 
cultured SMC, particularly when used in combination 
with other growth factors such as bFGF and PDGF- 
BB.  The data suggest several molecular mechanisms 
that may account for the ability of TGF-/3 to promote 
the growth of confluent SMC in culture. 
T 
hE replication of vascular smooth muscle cells (SMC)  ~ 
is tightly controlled in the adult animal and normally 
occurs only during tissue repair and angiogenesis. Ex- 
cessive or uncontrolled  SMC replication can be an important 
contributing  factor to a number of vascular disease states in- 
cluding  arteriosclerosis, hypertension,  and the reocclusion 
of vascular  grafts  and  endarterectomies  (7,  34,  38,  47). 
Much is now known concerning the factors that contribute 
to SMC growth control, based on studies of SMC replication 
in vitro. PDGF has been extensively implicated as an impor- 
tant positive regulator of SMC replication  (34, 35). At least 
three forms of PDGF are known to exist (for review, see ref- 
erence  14): homodimers of the A-chain  of PDGF, homo- 
dimers of the B-chain  of PDGF (products of the c-sis on- 
cogene), and A-B heterodimers.  The three dimeric forms of 
PDGF interact  selectively with at least two forms of PDGF 
receptors  (12, 13,  14).  The  specific  contributions  of the 
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different forms of PDGF in the control of SMC growth have 
not been completely elucidated. 
Other growth and accessory factors are probably equally 
important  in SMC growth control.  Those relevant  to this 
study include basic fibroblast growth factor (bFGF) (for re- 
view, see reference  16), thrombospondin  (TS) (21-24), and 
transforming  growth  factor-/3 (TGF-/$)  2 (3,  10, 20). TGF-/~ 
is of particular interest in the biology of vascular SMC in that 
it is very abundant in platelets (2, 3), is secreted by vascular 
endothelial  and SMC (1), and can either promote or inhibit 
the replication of SMC in vitro, depending on culture condi- 
tions.  When SMC are maintained  in two-dimensional  cul- 
ture, TGF-/3 can be a potent growth inhibitor (3, 20), but only 
when the cells are sparse (20). 
When the cells are confluent (20) or in soft agar (3), TGF-/3 
potentiates  SMC growth.  A combination  of these growth- 
inhibitory  and growth-promoting  effects is believed respon- 
sible for the establishment  and maintenance  of the "hill-and- 
valley" morphology common to SMC in culture (20).  In a 
separate  study  (10),  we have  shown  that  the  differential 
effects of TGF-/~ on SMC replication  may result from an in- 
2.  Unless otherwise specified,  "TGF-/~" refers to TGF-~I  homodimers. 
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pressed by SMC as a function of cell density. In this study, 
we describe the mechanisms whereby TGF-/3 promotes the 
growth of vascular SMC in confluent culture. We show that 
TGF-/3 can facilitate the growth of vascular SMC via the in- 
duced expression of PDGF, similar to previously reported data 
for fibroblasts and AKR-2B cells (18, 43). In addition, we de- 
scribe some of the growth-promoting effects of PDGF-AA. 
Materials and Methods 
Cell Culture 
Rat aortic SMC were derived from explants as previously described (21). 
Cells were maintained in culture in 5% calf serum (CS) in Waymonth's 
medium in the absence of antibiotics, and were used for experiments in the 
third through seventh passages.  Growth-arrested cells were obtained by 
maintaining cultures in 0.5% CS for 72 h as indicated. All tissue culture 
reagents were from Gibco Laboratories (Grand Island, NY). 
Growth Factors 
TGF-/3 from porcine platelets was purchased from R and D Systems (Min- 
neapolis,  MN),  as was porcine platelet PDGF  (PDGF-BB)  and human 
platelet PDGF (primarily PDGF-AB) (see references 6 and  11). Recom- 
binant human PDGF-AA was purchased from Collaborative Research, Inc. 
(Waltham, MA). The PDGF used for radioreceptor assays was prepared 
from outdated human platelets as described (32). Human recombinant basic 
FGF was prepared by Synergen, Inc.  (Boulder, CO). 
RNA Preparation 
Total  RNA from cultured cells was prepared using the SDS-proteinase K 
method (36). The quantity and purity of the samples were determined by 
spectrophotometric analysis by reading absorbances at 260 and 280 nm. 
Cells to be used for RNA preparations were grown in 150-mm diameter 
dishes and were washed 2-3x with cold (4°C) PBS before lysis. Typically, 
the yield of total RNA for sparse cells (plated at  1  x  10  a cells/cm  2) was 
50/zg RNA/dish. For confluent cells (plated at 5  x  104 cells/cm2), yields 
averaged 180/~g total RNA/dish. 
Northern Analysis 
For Northern analysis, RNA samples were denatured by glyoxylation and 
separated by electrophoresis through a 1.3 % agarose gel formed in 10 mM 
phosphate buffer (pH 6.8). The RNA was transferred electrophoretically to 
Genescreen Plus hybridization membranes (New England Nuclear, Boston, 
MA) overnight at 4°C at 20 V in tris acetate buffer containing EDTA, then 
was cross-linked to the filters by exposure to UV for 3 min. The filters were 
prehybridized for 10-30 min in 0.5 M sodium phosphate (pH 7.2) contain- 
ing 1 ram EDTA,  1% BSA, and 7% SDS, then were hybridized overnight 
at 65°C in the same buffer containing the DNA probe. Filters were washed 
in two changes of 0.1x  SSC/1%  SDS at 65°C, and then were exposed to 
Kodak XAR-5 film with Dupont Cronex intensifying screens at -70°C. To 
verify that equal amounts of RNA were loaded in each lane, relative levels 
of 28 and 18S ribosomal RNA were compared and the blots were probed 
with control cDNAs. 
SDS-PAGE 
SMC protein biosynthesis was analyzed by SDS-PAGE, as previously de- 
scribed (21).  Briefly,  SMC were metabolically labeled for 1 or 2 h with 
[3SS]methionine  (Amersham Corp.,  Arlington Heights,  IL)  in  medium 
lacking methionine. Radiolabeled proteins from SMC culture supernatants 
were precipitated in 10%  TCA, dissolved in Laemmli sample buffer con- 
taining DTT,  and resolved on 10%  polyacrylamide gels ~ontaining SDS. 
Proteins were visualized by autoradiography at -70°C using Kodak XAR-5 
film. Densitometric analysis of protein bands was performed on underex- 
posed films (to insure linear scanning conditions) using a Haake-Buchler 
scanning  densitometer  (Joyce-Loebl,  Malden,  CA).  Constitutively  ex- 
pressed internal reference proteins were used as standards. 
DNA Probes 
cDNA probes were oligo-labeled with [32p]dCTP  using random primers 
and  DNA polymerase (Pharmacia Fine Chemicals,  Uppsala,  Sweden). 
Typically,  200-300 ng of purified insert DNA was labeled to a specific ac- 
tivity of 108-109 cpm//~g,  cDNA probes used included a  1.5-kb  Barn HI 
fragment of a cDNA encoding human endothelial cell plasminogen activa- 
tor inhibitor, a 600-bp Pst I fragment of a eDNA encoding mouse type I 
procollagen, a 900-bp Sph I/Bum HI fragment of a cDNA encoding human 
fihronectin (FN), a 700-bp Pst I fragment of a cDNA encoding mouse/3-ac- 
tin, a 1.2 kb Pst I fragment ofa genomic clone encoding the v-sis oncogene 
(PDGF B-chain), a  1.3-kb  Eco RI fragment of a cDNA encoding the A 
chain of human PDGE and a 1.2 kb Eco RI/Sac I fragment ofa cDNA en- 
coding human TS. 
Mitogenesis Assays 
The mitogenic activity of TGF-~ and other growth factors was assessed by 
determining the uptake of [3H]thymidine in control (growth-arrested) and 
stimulated cells. Because initial experiments showed a clear difference be- 
tween the kinetics of S-phase entry in sparse and confluent cells, sparse cells 
were pulse-labeled for  1 h  at  16  h  poststimulation (during the peak of 
S-phase) while confluent cells were pulse-labeled for 1 h at 24 h. Briefly, 
the cells were labeled with 1 #Ci/ml [3H]thymidine in serum-free medium 
for 1 h, washed, and precipitated with 10%  TCA. Cells were solubilized 
in 0.3 N NaOH and the extent of uptake of [3H]thymidine was determined 
by scintillation counting. All experiments were done in triplicate, and data 
were normalized to a control value of 100% and presented as mean +  SEM. 
To corroborate the thymidine incorporation data, for certain experiments 
nuclear labeling indices were determined by autoradiography after exposure 
of the cells to [3H]thymidine  over a 32-h period as previously described 
(22). 
PDGF Radioreceptor Assay 
Levels of PDGF-like molecules in media conditioned by SMC were esti- 
mated by  radioreceptor assay  as previously described (5).  Cultures  of 
human diploid fibroblasts were incubated with increasing mounts of SMC- 
conditioned medium for 3 h at 4°C, rinsed with cold PBS, and then incubated 
with 12SI-labeled PDGF (5 ng/ml) for 1 h at 4°C. The cultures were rinsed 
three times with cold binding rinse, and bound  ~2SI-labeled PDGF  was 
solubilized with 2% Triton X-100. Purified human platelet PDGE consist- 
ing primarily ofAB heterodimers (11), was used as the standard. This assay 
detects PDGF-AA homodimers as well as PDGF-AB heterodimers. 
Results 
TGF-~ Regulates Connective 7Issue mRNAs in 
a Density Independent Fashion 
In a previous study (20), we showed that TGF-/3 exerted a 
bidirectional effect on SMC growth, depending on cell den- 
sity.  To  test  the  hypothesis that  TGF-/3 may  exert  these 
differential effects via a density dependent regulation of con- 
nective tissue gene expression (a common cellular response 
to TGF-~) (15, 30, 33), we determined mRNA levels for sev- 
eral connective tissue genes under conditions favoring TGF- 
/3-mediated growth inhibition (sparse SMC) and growth pro- 
motion (confluent SMC).  RNA was prepared from sparse 
proliferating SMC, sparse SMC growth inhibited by TGF-/3 
(10 ng/ml; 72 h), confluent SMC, and confluent SMC ex- 
posed to 10 ng/ml TGF-/3 for 72 h. The RNA was then sub- 
jected to Northern analysis as described in Materials and 
Methods. Steady-state mRNA levels for PAI-1 were identical 
in control and TGF-/3-treated cells, but were consistently 
higher in sparse cells. Message levels for/3-actin were de- 
creased by TGF-/~ under both culture conditions, while tran- 
scripts for fibronectin and type I collagen were induced by 
TGF-/3 independent of cell density (data not shown). These 
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Figure 1.  TGF-/3 potentiates mitogenicity in confluent SMC cul- 
tures.  Confluent SMC  cultures  were growth-arrested by serum 
deprivation (0.5% for 72 h), exposed to the indicated factors for 
24 h in the presence (+) or absence (-) of TGF-fl, pulse-labeled 
for 1 h with 1 /~Ci/ml [3H]thymidine, and then precipitated with 
10% TCA. The amount of [3H]thymidine incorporated into DNA 
was determined by scintillation counting, and all data were normal- 
ized to a value of 100% for the control (CON) cultures. TGF-/~ 
added alone (at 10 ng/ml) elicited a mitogenic response in confluent 
cultures and, when given in combination with other factors, poten- 
tiated the mitogenic responses to 10% CS, porcine platelet PDGF 
(10 ng/ml), and bFGF (10 ng/ml). In sparse cell cultures, TGF-~ 
inhibited the mitogenic responses to each of these factors at the 
same concentrations. 
results likely reflect a direct effect of TGF-/3 on the expres- 
sion of these genes, and suggest that the growth-inhibitory 
effects of TGF-~ in SMC are not causally related to connec- 
tive tissue production, as recently suggested for another cell 
type (29). 
TGF-~ Facilitates  Mitogenesis in Confluent, but Not 
Sparse, SMC Cultures 
Sparse and confluent SMC cultures were growth arrested by 
serum deprivation (0.5 % CS for 72 h), and then exposed to 
serum or purified growth factors for 16 h (sparse cells) or 
24 h (confluent cells) before a 1-h pulse labeling with [3H]thy- 
midine (1  /~Ci/ml).  As  shown in Fig.  1,  TGF-~ elicited a 
mitogenic response in quiescent confluent SMC cultures and 
potentiated the mitogenicity of serum, porcine platelet PDGF 
(consisting primarily of PDGF-BB), and human basic FGE 
The relatively weak stimulation of  mitogenesis observed was 
consistent among experiments and results from the fact that 
over-confluent, density-arrested cultures were used in these 
studies.  Addition of TGF-~ alone to  sparse  SMC did not 
elicit a  mitogenic effect, and was always inhibitory when 
added in combination with bovine serum, PDGF from hu- 
man or porcine platelets, or bFGF (data not shown). 
To verify the ability of TGF-/~ to act to elicit SMC mitt- 
genesis, nuclear labeling indices were determined on sparse 
and confluent SMC labeled with  [3H]thymidine during in- 
cubation with or without TGF-~ for 32 h. Samples were then 
processed for autoradiography. Growth-arrested SMC incu- 
bated without "I'GF-/3 showed relatively high labeling index 
values of 31.2  +  1.6% (possibly due to density-dependent 
activation of various autocrine/paracrine activities). None- 
theless, confluent SMC incubated in the presence of TGF-/~ 
exhibited a marked increase in the percent of labeled nuclei 
to 71.9 +  3.8% (Fig. 2). In contrast, TGF-# had no stimula- 
tory or inhibitory effect on the basal labeling index (<10%) 
of sparse, growth-arrested cultures of SMC.  TGF-/~, or an 
autocrine factor induced by TGF-/~, therefore elicits a mito- 
genic signal in confluent, but not sparse, SMC cultures. 
Thrombospondin Protein and mRNA Are Expressed 
during TGF-(3-mediated  Mitogenesis 
Our previous studies (21) have shown that SMC express in- 
creased amounts of two secreted proteins (sp55 and "IS) after 
mitogenic stimulation by serum or PDGE Since "IS secre- 
tion is believed to be essential for SMC replication (23) and 
may, in fact, exert growth-promoting effects of its own (22, 
39, 40), we sought to determine if "IS were induced during 
TGF-/~-mediated mitogenesis. In addition, a comparison of 
the kinetics of TS induction during TGF-/~-mediated mitt- 
genesis with that occurring during PDGF-mediated mitogene- 
sis should contribute to our understanding of the mechanisms 
underlying TGF-/~-mediated SMC replication. Growth-ar- 
rested SMC cultures were treated with TGF-/3 (10 ng/ml) for 
0-24 h, and then pulsed for 2 h with [35S]methionine.  Ra- 
diolabeled secreted proteins were analyzed by SDS-PAGE, 
autoradiography,  and  quantitative  scanning  densitometry. 
Addition of TGF-/~ to quiescent confluent SMC  resulted, 
within 4 h, in the induction of synthesis and secretion of'IS 
and sp55. Similar experiments were performed using human 
platelet PDGF, and the data were quantitated using scanning 
densitometry. As shown in Fig. 3, the TGF-/3-mediated in- 
duction of TS was delayed 2 h as compared to the PDGF- 
mediated induction.  Furthermore, the effect was longer in 
duration and of lesser magnitude in the TGF-/~-treated cul- 
tures. Similar results were observed for sp55 (data not shown). 
Neither sp55 nor "IS protein levels were induced by TGF-/~ 
in sparse SMC, at least within the time frame examined. 
We next examined the  ability  of TGF-~ to  induce  TS 
mRNA levels in quiescent confluent SMC, using Northern 
analysis of RNA prepared from cells treated for 1-5 h with 
10  ng/ml  TGF-/3.  As  shown  in  Fig.  4,  TGF-/3  caused  a 
gradual rise (first apparent at 2-3 h) in TS message levels, 
reaching threefold induction by 5 h. These data should be in- 
terpreted in view of our previous studies (24) that demon- 
strated a  significant (fourfold) induction of TS mRNA  in 
SMC within 30 min of treatment with PDGE The data dem- 
onstrate that, similar to 'IS protein levels (Fig. 2), the induc- 
tion of TS mRNA by TGF-~ also occurs with a delayed time 
course relative to its induction by PDGE TS message levels 
remained high at 24-, 48-, and 72-h time points in confluent 
cells only (see Fig. 5). Consistent with our protein data, "IS 
mRNA was not induced by TGF-/3 under sparse culture con- 
ditions at any of the time points examined (0-6-, 24-, 48-, 
and 72-h) (Fig. 5). 
The stimulation of TS mRNA accumulation by TGF-/3 ap- 
peared to be indirect in nature (Fig. 6). Confluent, quiescent 
SMC were treated with actinomycin D or cycloheximide be- 
fore a 4-h treatment with TGF-/3, cytoplasmic dot blots were 
prepared,  and the blots were hybridized with  labeled "IS 
cDNA.  In the presence of actinomycin D  (an inhibitor of 
DNA-dependent RNA transcription), the inductive effect of 
Majack et al.  TGF-B, PDGF-A, and SMC Growth Control  241 Figure 2.  Addition  of TGF-B to confluent  quiescent  SMC results  in an increase  in the nuclear labeling  index.  Confluent  SMC cultures 
were growth-arrested  by serum deprivation,  then were labeled  with  [3H]thymidine in the absence (a) or presence (b) of 10 ng/ml TGF-fl 
for 32 h. Cultures were then fixed, coated with emulsion and processed for autoradiography.  The percent  labeling  index for control cells 
(a) was 31.2  +  1.6%, compared with 71.9  +  3.8% for cells treated with TGF-/3 (b). Paired photomicrographs of SMC cultures  were taken 
with  phase-contrast (left) and bright  field optics (right). 
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Figure 3. Induced secretion of 
thrombospondin  by  TGF-~ 
occurs  with  delayed  kinetics 
relative  to  its  induction  by 
PDGF. SMC at confluent den- 
sities  were  treated  with  10 
ng/ml  human  platelet  PDGF 
or  TGF-fl  for  the  indicated 
times  and  secreted  proteins 
were analyzed as described in 
Materials  and  Methods.  Au- 
toradiographs  were  scanned 
and the relative optical density 
of  TS  was  determined  and 
normalized  to  constitutively 
expressed  proteins.  Secretion 
of TS occurs with delayed ki- 
netics  in response to TGF-/L 
In addition, the effect was gen- 
erally of longer duration and 
of lesser intensity as compared 
to that mediated  by PDGE 
TGF-fl on TS message levels was completely abolished.  As 
previously shown (24), cycloheximide alone exerted a slight 
inductive effect on TS mRNA (presumably due to stabiliza- 
tion of the TS message), Addition of TGF-fl together with cy- 
cloheximide did not increase TS mRNA levels above those 
observed for cycloheximide alone. These data are in contrast 
to the synergistic effects of PDGF and cycloheximide, that 
combine to "superinduce" the TS message in similar experi- 
ments reported previously (24) and repeated here (Fig.  6). 
The data suggest that the stimulatory effect of TGF-/3 on TS 
message  levels  requires  de  novo protein  synthesis  and  is 
therefore indirect in nature. 
TGF-/3-treated SMC Express Induced Amounts 
of  PDGF-A mRNA and Secrete Increased Amounts of 
PDGF-like Protein 
Because the induction of TS protein and mRNA by TGF-/3 
was delayed and indirect, and because the pattern of secreted 
proteins  induced during TGF-/3-mediated mitogenesis was 
identical to that induced by PDGF, we examined the possibil- 
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6.0  els in response to TGF-/3 ap- 
"~  4.0  pears  to  be  indirect.  SMC 
.~  at  confluent  densities  were 
2.0  ~  growth-arrested  by serum de- 
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,=  1.0  4 h with TGF-B with or with- 
"~  Con TGF-p CH  TGF-p  ACl D  TGF-p  PDGF  POGF  ÷  out cycloheximide (CH) or ac- 
cord  ~  tinomycin D (Act D). Control 
cells(Con) received no additions.  Cytoplasmic dot blots were pre- 
pared and hybridized with a eDNA specific  for TS. The resultant 
autoradiographs were quantitated  by scanning densitometry.  Both 
TGF-/3 and CH, when added alone, caused increases in steady-state 
TS mRNA levels; TGF-/3 did not further enhance the response to 
CH when cells were treated with TGF-/3  and CH together. For com- 
parison, the inductive  effects of a 2-h PDGF treatment with and 
without prior CH treatment (which "superinduces" the TS message) 
(24) are also shown. 
Figure 4.  TS mRNA levels are elevated  within  3 h after addition 
of TGF-/3 to quiescent confluent  SMC. SMC at confluent densities 
were growth-arrested  by serum deprivation,  then were treated with 
10 ng/ml TGF-/3 for the indicated  times.  10 #g of total RNA per 
lane was subjected to Northern analysis for thrombospondin  mRNA 
levels. The induction of TS mRNA levels was gradual and was de- 
tectable only after 2-3 h of addition  of TGF-/3 to the cultures. 
ity that TGF-/3 regulates the production of PDGE Sparse and 
confluent SMC were growth arrested early in Gt by main- 
taining the cultures for 72 h in low (0.5 %) serum. Total RNA 
was isolated  from SMC  treated  with  10 ng/ml  TGF-fl for 
0-24 h  and Northern blots were prepared.  The blots were 
probed with cDNAs specific for the A and B chains of PDGF. 
Message for PDGF B-chain (c-sis) could not be detected in 
SMC under quiescent (serum-starved) or TGF-/3-treated con- 
ditions (data not shown). The same Northern blots revealed 
strong hybridization signals when probed for A-chain message 
(Fig. 7). Three distinct mRNA species in SMC are frequent- 
ly detected  by A  chain probes,  corresponding to message 
sizes of 2.9-, 2.3-, and 1.7-kb.  TGF-fl treatment of quiescent 
SMC resulted in the rapid accumulation (first apparent at 1 h) 
of the 2.3-kb  species of A-chain mRNA (Fig.  1).  Identical 
results were obtained when RNA was examined from sparse 
or confluent SMC. 
Radioreceptor assays were used to estimate the amount of 
PDGF-like  protein  in  control  and  TGF-/3-treated  SMC- 
conditioned  media.  Cells  at  sparse  or confluent  densities 
were growth arrested in 0.5 % CS for 72 h, then were treated 
with TGF-~ for 24 h. The culture supernatants were removed 
and replaced with serum-free media with or without TGF-/3; 
ceils were allowed to condition this medium for an additional 
24 h. PDGF-like activity in culture supernatants of untreated 
SMC,  as well as in serum-free media incubated in the ab- 
sence of cells, was below reliable limits of detection for the 
assay. In contrast, both sparse and confluent SMC secreted 
readily detectable amounts of PDGF-like activity (0.15-0.41 
ng/ml) after  TGF-/3 treatment.  We therefore conclude that 
TGF-/3 stimulates  PDGF gene expression and secretion by 
Figure  5.  TS  mRNA levels  are  selectively  increased  in TGF-/% 
treated confluent cells. SMC at sparse (lanes 1 and 2) and confluent 
(lanes 3 and 4) densities  were left untreated  (lanes 1 and 3) or were 
exposed to 10 ng/ml TGF-/3 for 72 h (lanes 2 and 4).  10 #g of total 
RNA was  subjected  to Northern analysis  for TS message.  Mes- 
senger mRNA levels  for TS are markedly increased  in confluent 
cells  stimulated  with TGF-/3 while  message  levels  in sparse  in- 
hibited  cells are unaffected. 
Figure  7.  TGF-/3 regulates 
steady-state  mRNA levels for 
the A-chain of PDGE Quies- 
cent  confluent  SMC  were 
treated  with  10 ng/ml  TGF-/3 
for the indicated times.  10 #g 
of total  RNA  per  lane  was 
subjected  to Northern analy- 
sis for PDGF A-chain mRNA. 
A rapid and sustained increase 
in A-chain transcripts  (2.3-kb 
species) occurs in response to 
TGF-/3 treatment. 
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for 1 h to determine relative rates of DNA synthesis. PDGF-AA was 
able to elicit a  significant mitogenic response  at  concentrations 
>5 ng/ml; maximum DNA synthesis was induced at 50 ng/ml. 
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Figure  10.  TGF-/3  inhibits  PDGF-AA-mediated  mitogenesis  in 
sparse  SMC cultures.  Sparsely plated,  quiescent SMC were ex- 
posed to TGF-~ (10 ng/ml) and PDGF-AA (50 ng/ml) alone or in 
combination.  Cells were pulse-labeled with [3H]thymidine at  16 h. 
PDGF-AA, but not TGF-fl was mitogenic for sparse SMC. TGF-~ 
inhibited the mitogenesis induced by PDGF-AA. 
may be expressed at very low levels, and that small amounts 
of PDGF-AB and/or -BB may be present. 
Induced PDGF Expression Accounts for the Mitogenic 
Activity of TGF-[3 
To  determine  the  possible  role  of PDGF-Iike  proteins  in 
mediating the growth-promoting effects of TGF-fl,  we tested 
anti-PDGF IgG for their ability to neutralize the increase in 
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Figure 11. PDGF-AA acts cooperatively with bFGF and PDGF-BB 
to stimulate SMC mitogenesis. Confluent quiescent SMC were ex- 
posed to the indicated growth factors for 24 h, and then were pulse- 
labeled with [3H]thymidine.  While PDGF-AA (50 ng/ml), bFGF 
(10  ng/ml),  and  PDGF-BB (50 ng/ml) each gave relatively weak 
mitogenic  responses  when  added  alone,  when  PDGF-AA  was 
added in combination with bFGF or PDGF-BB, the mitogenic re- 
sponses were markedly enhanced. 
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The antibodies used (a generous gift of E.  Raines and R. 
Ross, University of Washington) were prepared against hu- 
man platelet PDGF (which is predominantly PDGF-AB) but 
show some neutralizing ability against PDGF-AA (31).  As 
shown  in  Fig.  8,  very high  amounts  of this  antisera  (20 
mg/ml) significantly reduced the increase in cell number in- 
duced by TGF-/3 over a 48-h period. Control antisera (also 
at 20 mg/ml) did not block the TGF-~ mediated increase in 
cell number. On the basis of these data, we concluded that 
the induced expression of a PDGF-Iike activity was primar- 
ily responsible for the growth-promoting effects of TGF-/& 
PDGF-AA Is Weakly Mitogenic for Sparse and 
Confluent SMC in Culture 
While  PDGF-AB and  PDGF-BB are  known mitogens for 
cultured vascular  SMC  (32,  35),  several recent abstracts 
offered contradictory statements concerning the mitogenic 
effects of PDGF-AA on cultured SMC (Blank, R. S., M. H. 
Corjay, and G. K. Owens. 1989. FASEB  [Fed. Am. Soc. Exp. 
Biol.] J. 3:A611  [abstr.]; Gibbons, G. H., R. E. Pratt, and 
V. J. Dzano. 1989. J. Cell Biochem. Suppl. 13E:191 [abstr.]). 
Because our data strongly suggest a role for PDGF-AA in the 
control of SMC replication by TGF-/~, we sought to deter- 
mine the effects of AA homodimers on the replication of the 
rat aortic SMC used in this study.  As presented in Fig. 9, 
recombinant human PDGF-AA caused a dose-dependent in- 
crease in [3H]thymidine uptake by confluent SMC,  with a 
maximal effect observed at 50 ng/ml. As presented below, 
AA homodimers were also weakly mitogenic for sparse SMC. 
In additional experiments not shown, PDGF-AA (at 50 ng/ 
ml) was found to stimulate the expression of  thrombospondin 
and sp55, similar to the effects of PDGF-AB (human platelet 
PDGF) (21).  These are expected results given that PDGF- 
AA and -AB are believed to interact with a common receptor 
(6,  12-14). 
The Growth Inhibitory Effects of TGF-f3 Override 
the Mitogenic Effects of PDGF-AA in Sparse 
SMC Cultures 
As  noted above, PDGF-A was  induced by TGF-/3 in both 
sparse and confluent cultures, while TGF-~-mediated mito- 
genesis was observed only in confluent cultures. Conceiv- 
ably, this differential effect could result from an ability of 
PDGF-AA to override the growth inhibitory effects of TGF-fl, 
coupled with  a  lack of responsiveness of sparse  SMC to 
PDGF-AA.  To  test  this  possibility,  we  treated  quiescent 
sparse SMC with TGF-/~ (10 ng/ml) and AA homodimers (50 
ng/ml)  alone and  in  combination.  As  shown  in  Fig.  10, 
PDGF-AA was clearly mitogenic for sparse cells, and this 
mitogenicity was completely inhibited by the simultaneous 
addition of TGF-/3. These data are fully consistent with the 
demonstrated ability of TGF-# to  inhibit serum-,  bFGF-, 
PDGF-BB-, and PDGF-AB-mediated mitogenesis in sparse 
SMC cultures. The data suggest that sparse SMC respond to 
TGF-/~ with a dominant growth inhibitory signal that is com- 
pletely dissociable from  its  effects on growth  factor pro- 
duction. 
PDGF-AA Acts Cooperatively  with Other Growth 
Factors during SMC Mitogenesis 
If PDGF-A expression is responsible for the potentiation of 
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Figure 12.  Hypothetical roles for TGF-/~, "rGF-/~ receptors,  and 
PDGF-AA in the control of SMC growth in vitro. Sparse and con- 
fluent cultured SMC express distinct TGF-/~ receptor phenotypes 
(10). Exposure of sparse SMC to TGF-~ (a) results in the induced 
expression of FN, type I collagen (col-I), and PDGF-A. Cell growth 
in response to a variety of stimuli is inhibited, suggesting a domi- 
nant growth inhibitory block somewhere in the G~ phase of the 
cell cycle. When confluent SMC are exposed to TGF-/3 (b), cell 
growth in response to a variety of stimuli is enhanced or unaffected 
rather than inhibited, suggesting that confluent SMC are refractory 
to the growth inhibitory effects  of TGF-fl. The TGF-fl-mediated en- 
hancement of proliferation results from the mitogenic activity of the 
induced PDGF  (which we presume to be primarily  AA homo- 
dimers), as well as from the increased expression of  TS and the abil- 
ity of PDGF-AA to act cooperatively with other mitogens such as 
bFGF and PDGF-BB. 
SMC mitogenesis that occurs when TGF-fl is added in com- 
bination with serum or other growth factors (see Fig. 1), then 
purified PDGF-AA should act similarly to potentiate mito- 
genesis. To test this hypothesis, we performed mitogenesis 
assays  on  quiescent  confluent  SMC  using  recombinant 
PDGF-AA, porcine platelet PDGF (PDGF-BB), and bFGE 
As presented in Fig.  11, PDGF-AA (50 ng/ml) acted in con- 
cert with bFGF  (10  ng/ml) and PDGF-BB (50 ng/ml) to 
stimulate mitogenesis under these conditions. Similar results 
were obtained in experiments using sparse cells. 
Discussion 
Multifunctional regulatory peptides such as PDGF (for re- 
view, see references 14, 35) and TGF-fl (for review, see refer- 
ences 28, 44, 45) are believed to play important roles in vas- 
cular  biology during  development,  in  homeostatic tissue 
maintenance,  and in tissue repair after injury. TGF-B has 
been shown to regulate the behavioral organization of vascu- 
lar SMC in culture (20) and may inhibit (3, 20) or promote 
(3, 20) SMC replication, depending on culture conditions. 
In  a  previous  study,  we  have provided evidence that the 
differential effects of TGF-fl on SMC growth may result from 
an interaction of TGF-fl with distinct, selectively expressed, 
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our examination into the effects of TGF-B on SMC replica- 
tion  and  gene  expression  in  vitro  with  an  emphasis  on 
elucidating the mechanisms underlying the growth promot- 
ing effects of TGF-B on confluent SMC. 
In Vitro Responses of Sparse SMC to TGF-/3 
Fig. 12 presents a comprehensive summary of our data con- 
cerning the hypothesized roles of TGF-/3, TGF-13 receptors, 
PDGF-A, and cell density in the control of SMC replication 
in vitro. Vascular SMC maintained at sparse density in cul- 
ture express two predominant TGF43 binding proteins on 
their cell surfaces, with receptor-ligand complexes of Mr = 
65,000 and 75,000 (10). Because the ability of TGF-/3 to act 
as a growth inhibitor for SMC correlates with the expression 
of the 75-kD "receptor" we have hypothesized that this re- 
ceptor-subunit mediates a growth inhibitory response in these 
cells (10). Sparse SMC express increased amounts of fibro- 
nectin and type I collagen mRNA in response to TGF-/~ (as 
do confluent cells). TGF-B-treated sparse SMC express mark- 
edly increased amounts of the PDGF-A message and secrete 
increased amounts of PDGF-A homodimers, which, as we 
have shown in this study (Figs. 9-11),  are clearly mitogenic 
for rat aortic SMC.  It seems obvious that TGF-B elicits a 
dominant growth inhibitory response in sparse SMC that is 
unrelated to its effects on connective tissue or PDGF-A ex- 
pression. TGF-B can inhibit the growth of sparse SMC repli- 
cating in 5 % CS (20), and can inhibit the mitogenic response 
of sparse SMC to EGF (3), PDGF-AB, PDGF-BB, PDGF-AA, 
bFGF, and CS (this study). The mechanisms underlying the 
growth inhibitory effect of TGF-/~ on sparse SMC are pres- 
ently unknown and are the focus of ongoing investigation. 
In Vitro Responses of Confluent SMC to TGF-f3 
Exposure of confluent vascular SMC to TGF-/3 results in the 
accumulation of FN, type I collagen, and PDGF-A mRNA 
transcripts with kinetics similar to that observed in sparse 
SMC. As shown in our previous work (20) and reiterated in 
this study (Fig. 1), confluent SMC cultures appear refractory 
to the growth inhibitory effects of TGF43. Without such a 
TGF-l%mediated block to cellular proliferation, the cells 
can respond to autocrinely produced PDGF alone or in con- 
cert with other growth factors (Fig.  11), resulting in growth 
promotion. It should be emphasized here that, although we 
have concentrated on the effects of induced PDGF-A in TGF- 
/3-mediated growth stimulation, our data do not rule out the 
involvement of other growth factors in this process. 
TS Expression during TGF-fJ-mediated Mitogenesis 
TS, an Mr =450,000 homotrimeric secreted glycoprotein, is 
expressed during TGF-~-mediated mitogenesis (Figs. 3-5). 
Thrombospondin was previously shown to be regulated by 
PDGF in vascular SMC (21), and the regulation was shown 
to occur at the mRNA level (17, 24). TS is believed to be es- 
sential for SMC proliferation (23),  and may play a role in 
the response of SMC to other growth factors (22, 40). Petti- 
nen et al. (30) have demonstrated, in 3T3 fibroblasts,  the in- 
duction of "IS message by TGF-/3; however, it was not deter- 
mined if  this was a direct effect or one requiring the synthesis 
of  a protein intermediate (e.g., PDGF). Our data, which show 
that the TGF-/~-induced expression of TS is density-depen- 
dent, of slow onset, and cycloheximide-sensitive, strongly 
suggest that the effect is indirect, mediated via the induced 
secretion of a PDGF-like activity (probably PDGF-AA). Re- 
gardless of the underlying mechanism, the expression of TS 
during TGF-~-mediated mitogenesis suggests an additional 
way in which TGF-/5 can positively influence SMC growth 
in confluent cultures (22,  39). 
Role of PDGF-A in SMC Growth Control 
TGF-/3 is known to regulate the expression of PDGF genes 
in several  systems, including vascular endothelial cells (8, 
46), leukemia cells (27),  AKR-2B cells (18), and human fi- 
broblasts (43);  autocrine PDGF-mediated growth stimula- 
tion has been proposed for the latter two examples. Vascular 
SMC are known to express PDGF-A under certain culture 
conditions (19, 25, 41, 42), but the functional consequences 
of A-chain expression have not been elucidated. Several con- 
flicting preliminary reports exist that address the issue of the 
mitogenicity of PDGF-A on cultured SMC. In this study, we 
have demonstrated that AA homodimers are weakly mito- 
genie for cultured rat aortic SMC (Figs.  9-11).  In addition, 
we provide evidence that PDGF-AA can act synergistically 
with other growth factors (e.g., bFGF and PDGF-BB) to 
stimulate SMC mitogenesis. The available  evidence there- 
fore suggests that the induced expression of PDGF-A can 
facilitate SMC replication in two ways: PDGF-AA can act in- 
dividually as a mitogen, and can cooperate with other growth 
factors to facilitate their mitogenic activity. As demonstrated 
by the data presented in Fig. 10, the TGF-B-mediated induc- 
tion of PDGF-A in sparse SMC would not be expected to 
influence DNA synthesis since, in sparse cells, TGF-B in- 
hibits mitogenesis in response to PDGF-AA and all other 
growth stimuli tested to date. 
The demonstration that TGF-B can facilitate the replica- 
tion of confluent SMC may explain the heretofore puzzling 
observations that TGF-/5 mRNA is induced in the vascular 
wall during tissue repair following balloon catheterization 
(Majesky, M. W., M. A. Reidy, D. R. Twardzik, and S. M. 
Schwartz. 1989. FASEB  [Fed. Am. Soc. Exp. Biol.] J. 3:A298 
[abstr.]),  and during vascular wall remodeling associated 
with the development of hypertension (37).  Other  recent 
studies have shown that infusion of TGF-B after balloon cath- 
eterization injury of the rat carotid artery results in a signifi- 
cant stimulation of SMC replication in the neointima (M. 
Reidy, personal communication). Thus, SMC in vivo may 
respond, as could be predicted, as "confluent" SMC do in 
vitro. We propose that TGF-/~ may be an important regula- 
tory molecule involved in many aspects of vascular growth, 
tissue repair, and development. Our data emphasize the mul- 
ti  functionality of TGF-B in vascular biology, and show that 
some of this multifunctionality may arise from the induced 
production of other autocrine regulatory factors. The data 
also demonstrate that the pleiotropic effects of TGF-B can be 
functionally dissociated from one another, and strongly sug- 
gest that the in vivo responses of SMC to TGF-~ may vary 
considerably deRending  on the biological situation. 
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